The city of Los Angeles, California, currently has 379 active clinical trials seeking participants for Cancer research studies.
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
Recruiting
This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered orally.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/29/2023
Locations: University of Southern California, Los Angeles, California +1 locations
Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Recruiting
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: University of Southern California, Los Angeles, California
Conditions: Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
Recruiting
This trial will evaluate the use of immunotherapy and PARP inhibition in a population with incurable advanced breast cancer associated with a germline BRCA mutation or HDR-defect. The main objective is to examine overall response rate of pembrolizumab (immunotherapy) in combination with Olaparib (PARP inhibitor) in advanced BRCA-mutated or Homology-directed repair (HDR)-defect breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Breast Cancer
Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions
Recruiting
The purpose of this study is to determine whether quantitative contrast-enhanced endoscopic ultrasound (CE-EUS) improves the evaluation of pancreas tumors and precursor lesions, including cysts, compared to conventional endoscopic ultrasound.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/13/2023
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Pancreatitis, Pancreas Cancer, Pancreas Cyst
Childhood Cancer Survivor Study
Recruiting
The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of cancer and its associated therapies. A retrospective cohort study will be conducted through a multi-institutional collaboration, which will involve the identification and active follow-up of a cohort of approximately 50,000 survivors of cancer, diagnosed before 21 years of age, between 1970 and 1999 and 10,000 sibling controls. This project will study children and young adults exposed to specific therapeutic mod... Read More
Gender:
All
Ages:
All
Trial Updated:
12/11/2023
Locations: Children's Hospital Los Angeles, Los Angeles, California +1 locations
Conditions: Cancer
A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors
Recruiting
The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
12/08/2023
Locations: The Angeles Clinic and Research Institute, Los Angeles, California +1 locations
Conditions: Solid Tumor, Adult, NSCLC, Urothelial Carcinoma, Gastric Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma, Cervical Carcinoma, Melanoma, Renal Cell Carcinoma, Carcinoma
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
12/08/2023
Locations: UCLA - JCCC Clinical Research Unit, Los Angeles, California
Conditions: Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
12/08/2023
Locations: UCLA - JCCC Clinical Research Unit, Los Angeles, California
Conditions: Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
Recruiting
The purpose of this study is to test the safety and tolerability of HFB200603 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses of HFB200603 as a monotherapy or in combination with tislelizumab until a safe and tolerable dose of HFB200603 as a single agent or combination therapy is determined. During the expansion part, participants will take... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer, Colorectal Cancer
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
Recruiting
This phase I trial evaluates the side effects of radio-immunotherapy (CDX-301, radiotherapy, CDX-1140 and Poly-ICLC) in treating patients with unresectable and measurable metastatic melanoma, cutaneous squamous cell carcinoma (SCC), Merkel cell carcinoma, high-grade bone and soft tissue sarcoma or HER2/neu(-) breast cancer. CDX-301 may induce cross-presenting dendritic cells, master regulators in the immune system. Radiation therapy uses high energy to kill tumor cells and release antigens that... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Unresectable Breast Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Soft Tissue Sarcoma, Bone Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Recruiting
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: UCLA, Los Angeles, California
Conditions: ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Recruiting
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/17/2023
Locations: UCLA Medical Center, Los Angeles, California
Conditions: Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors